Lialda Shortage Update: What Patients Need to Know in 2026

If you've heard that Lialda is in shortage, or if you've personally had trouble filling your mesalamine prescription, you're probably wondering: is there actually a shortage, and will it get better? Here's the clearest answer we can give you for 2026.

Is Lialda in an Official Shortage in 2026?

No. As of 2026, Lialda (mesalamine 1.2 g delayed-release tablets) and its generic equivalents are NOT on the FDA's official active drug shortage list. The FDA shortage database tracks medications where manufacturing supply is genuinely insufficient to meet national demand. Lialda does not meet that definition.

It's worth noting that a different mesalamine product — mesalamine extended-release 500 mg capsules (a Pentasa-formulation generic) — has had shortage issues, with Sun Pharma reporting a back-order as of early 2026. But this is a completely different formulation from Lialda's delayed-release tablets.

Why Are Some Patients Struggling to Fill Lialda Prescriptions?

Even without a formal shortage, many patients report difficulty getting Lialda filled. Here's why:

• Brand Lialda is being replaced by generics: Most large chain pharmacies have shifted to stocking generic mesalamine 1.2 g delayed-release tablets instead of brand Lialda. If your prescription specifies "Lialda brand only," your pharmacist may not have it.
• Mesalamine ER capsules (a different product) are in shortage: The ASHP reported shortages of mesalamine 500 mg ER capsules. Patients confusing this with their Lialda tablets may receive incorrect information about their specific medication.
• Local inventory management: Automated pharmacy ordering systems allocate shelf space based on dispensing volume. Low-volume drugs get minimal stock, creating localized gaps.
• Insurance barriers: Many plans require step therapy (trying a generic first) or prior authorization before covering Lialda. Processing delays can look and feel like a "shortage" even when supply exists.

What's the History of Lialda Availability?

Lialda was first approved by the FDA on January 16, 2007 and launched in the first quarter of 2007 as the first once-daily oral mesalamine. It was a significant advance for ulcerative colitis patients because prior products required three to four daily doses.

Generic mesalamine 1.2 g delayed-release tablets have been available for several years, with manufacturers including Zydus Pharmaceuticals, Camber Pharmaceuticals, Mylan, and Teva. The entry of multiple generics has driven prices down dramatically and improved overall market availability of this formulation.

What If There IS a Shortage in the Future?

If mesalamine delayed-release tablets do enter a formal shortage, patients with ulcerative colitis would have several important considerations:

• Don't abruptly stop mesalamine — this can trigger a UC flare
• Contact your gastroenterologist immediately for guidance
• Consider switching to another aminosalicylate formulation (Delzicol, Pentasa, Asacol HD) with your doctor's guidance
• Rectal mesalamine (suppositories or enemas) can be used as a bridge for patients with distal colitis

What Can You Do Right Now?

Whether or not there's a formal shortage, if you're having trouble filling your Lialda prescription, here are your immediate action steps:

1. Use medfinder — medfinder.com calls pharmacies near you to find which ones have your medication in stock.
2. Ask for generic mesalamine DR — Generic mesalamine 1.2 g delayed-release tablets are bioequivalent to Lialda and far more widely available.
3. Call your doctor — If you cannot get any mesalamine formulation, don't wait. Your doctor can discuss alternatives and ensure your UC is managed.
4. Build a small buffer supply — Once you get your prescription filled, ask your doctor about a 90-day supply through mail order. Having extra supply reduces your exposure to future pharmacy stock issues.

The Bottom Line

Lialda (mesalamine delayed-release tablets) is not in a formal FDA shortage in 2026. Access challenges are real but are primarily driven by brand-to-generic transitions and local pharmacy inventory practices rather than a national supply crisis. Generic mesalamine DR is widely available and is the simplest solution for most patients. See our full guide: How to find Lialda in stock near you